GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » Scaled Net Operating Assets

Walvax Biotechnology Co (SZSE:300142) Scaled Net Operating Assets : 0.52 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Walvax Biotechnology Co's operating assets for the quarter that ended in Mar. 2024 was ¥11,274 Mil. Walvax Biotechnology Co's operating liabilities for the quarter that ended in Mar. 2024 was ¥3,149 Mil. Walvax Biotechnology Co's Total Assets for the quarter that ended in Dec. 2023 was ¥15,589 Mil. Therefore, Walvax Biotechnology Co's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.52.


Walvax Biotechnology Co Scaled Net Operating Assets Historical Data

The historical data trend for Walvax Biotechnology Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co Scaled Net Operating Assets Chart

Walvax Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.85 0.71 0.55 0.51

Walvax Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.53 0.52 0.50 0.52

Competitive Comparison of Walvax Biotechnology Co's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Walvax Biotechnology Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Walvax Biotechnology Co's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Walvax Biotechnology Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Walvax Biotechnology Co's Scaled Net Operating Assets falls into.



Walvax Biotechnology Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Walvax Biotechnology Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(11224.334-3387.085)/15336.026
=0.51

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=15588.869 - 4364.535
=11224.334

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4193.509 - 455.491 - 350.933
=3387.085

Walvax Biotechnology Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2024 )
=(Operating Assets (Q: Mar. 2024 )-Operating Liabilities (Q: Mar. 2024 ))/Total Assets (Q: Dec. 2023 )
=(11274.394-3148.529)/15588.869
=0.52

where

Operating Assets(Q: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=15386.882 - 4112.488
=11274.394

Operating Liabilities(Q: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3953.21 - 448.255 - 356.426
=3148.529

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Walvax Biotechnology Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Walvax Biotechnology Co (SZSE:300142) Business Description

Traded in Other Exchanges
N/A
Address
Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106
Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.
Executives
Wu Yun Yan Executives
Zhao Jin Long Executives
Yao Wei Executives
Zhou Hua Executives
Shi Jing Executives
Jiang Run Sheng Directors, executives
Gong Sun Qing Executives
Executives
Yuan Lin Executives
Fang Guo Liang Executives
Li Yun Chun Director
Huang Zhen Director
Zhang Li Secretary Dong
Yang Hong Wei Supervisors
Xu Ke Ren Executives

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines